TOP TIERMARKET NEWSWIRE

News & sentiment

ALTIMMUNE INC (ALT) — News & AI sentiment

ALTIMMUNE INC (ALT) news roundup. 10 stories in the past week, 12 over 30 days. Average 30-day sentiment is 64.9/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

10

avg sentiment 65.3/100

30d stories

12

avg sentiment 64.9/100

Insider net (90d)

$0

0 buys · 0 sells

Congress (90d)

0

0 buys · 0 sells

Latest stories on ALT

ALT Stock Reverses Early Gains On Positive Alcohol Use Trial — But Wall Street, Retail Investors Dismiss Selloff

Stocktwits News54 · neutralproduct/pr

2d ago

Altimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol Use Disorder - Slideshow

Seeking Alpha50 · neutralgeneral

2d ago

Altimmune Shares Jump Premarket After Positive Results in Phase 2 Trial of Pemvidutide

Morningstar73 · bullishproduct/pr

2d ago

Altimmune’s Investigational Therapy For Alcohol Use Disorder Meets Primary Endpoint – ALT Stock Jumps 10%

Stocktwits News73 · bullishproduct/pr

2d ago

Altimmune Shares Jump After Positive Phase 2 Alcohol Use Disorder Trial Results

InvestorsHub73 · bullishproduct/pr

2d ago

Altimmune Reports Positive Phase 2 Data in AUD

TipRanks67 · bullishproduct/pr

2d ago

Altimmune rises as GLP-1 cuts drinking in mid-stage trial

Seeking Alpha73 · bullishproduct/pr

2d ago

Altimmune stock surges 18% on positive trial results

Investing.com Markets73 · bullishproduct/pr

2d ago

Altimmune, Inc. (ALT) files 8-K

SEC 8-K50 · neutralgeneral

2d ago

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder | ALT Stock News

StockTitan67 · bullishproduct/pr

2d ago

Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade

Seeking Alpha63 · neutralanalyst

Jul 7

Leerink Sees Altimmune (ALT) As An Attractive Play In The MASH Therapeutics Market

Yahoo Finance63 · neutralanalyst

Jul 5

Is Altimmune, Inc. (ALT) Still a Buy After Price Target Reduction to $20?

Yahoo Finance56 · neutralanalyst

Jun 24

Altimmune shifts headquarters to New Jersey, targeting biopharma talent and cost savings

Seeking Alpha56 · neutralgeneral

Jun 17

Altimmune Relocates Corporate Headquarters to Morristown, New Jersey

TipRanks55 · neutralgeneral

Jun 16

Altimmune, Inc. (ALT) files 8-K

SEC 8-K50 · neutralgeneral

Jun 16

Altimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha55 · neutralgeneral

Jun 10

Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026 | ALT Stock News

StockTitan67 · bullishproduct/pr

May 28

Altimmune to Participate in Upcoming Investor Conferences | ALT Stock News

StockTitan50 · neutralgeneral

May 27

New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026 | ALT Stock News

StockTitan67 · bullishproduct/pr

May 27

Altimmune, Inc. (ALT) Q1 2026 Earnings Call Transcript

Seeking Alpha50 · neutralearnings

May 14

Altimmune Q1 Earnings Call Highlights

Yahoo Top56 · neutralearnings

May 13

Altimmune shares climb after first-quarter loss beats expectations (ALT)

Yahoo Top63 · neutralearnings

May 13

Open ALT in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →